Reassuring Data for Cardiovascular Health After Switching a Boosted Protease Inhibitor to Dolutegravir
Clin Infect Dis
.
2023 Oct 5;77(7):1010-1011.
doi: 10.1093/cid/ciad298.
Author
Brian R Wood
1
Affiliation
1
Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, USA.
PMID:
37207616
DOI:
10.1093/cid/ciad298
No abstract available
Keywords:
HIV; antiretroviral; heart disease risk factors; hypertension; integrase inhibitors.